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Aim High-density lipoproteins (HDLs) have several potentially protective vascular effects. Most clinical studies of therapies
targeting HDL have failed to show benefits vs. placebo.
Objective To investigate the effects of an HDL-mimetic agent on atherosclerosis by intravascular ultrasonography (IVUS) and quan-
titative coronary angiography (QCA).
Design and
setting
A prospective, double-blinded, randomized trial was conducted at 51 centres in the USA, the Netherlands, Canada, and
France. Intravascular ultrasonography and QCA were performed to assess coronary atherosclerosis at baseline and
3 (2–5) weeks after the last study infusion.
Patients Five hundred and seven patients were randomized; 417 and 461 had paired IVUS and QCA measurements, respectively.
Intervention Patients were randomized to receive 6 weekly infusions of placebo, 3 mg/kg, 6 mg/kg, or 12 mg/kg CER-001.
Main outcome
measures
The primary efficacy parameter was the nominal change in the total atheroma volume. Nominal changes in per cent ath-
eroma volume on IVUS and coronary scores on QCA were also pre-specified endpoints.
Results The nominal change in the total atheroma volume (adjusted means) was 22.71, 23.13, 21.50, and 23.05 mm3 with
placebo, CER-001 3 mg/kg, 6 mg/kg, and 12 mg/kg, respectively (primary analysis of 12 mg/kg vs. placebo: P ¼ 0.81).
There was also no difference among groups for the nominal change in per cent atheroma volume (0.02, 20.02, 0.01,
and 0.19%; nominal P ¼ 0.53 for 12 mg/kg vs. placebo). Change in the coronary artery score was 20.022, 20.036,
20.022, and 20.015 mm (nominal P ¼ 0.25, 0.99, 0.55), and change in the cumulative coronary stenosis score
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was 20.51, 2.65, 0.71, and 20.77% (compared with placebo, nominal P ¼ 0.85 for 12 mg/kg and nominal P ¼ 0.01 for
3 mg/kg). The number of patients with major cardiovascular events was 10 (8.3%), 16 (13.3%), 17 (13.7%), and
12 (9.8%) in the four groups.
Conclusion CER-001 infusions did not reduce coronary atherosclerosis on IVUS and QCA when compared with placebo. Whether
CER-001 administered in other regimens or to other populations could favourably affect atherosclerosis must await
further study.
Name of the trial registry: Clinicaltrials.gov; Registry’s URL: http://clinicaltrials.gov/ct2/show/NCT01201837?term=
cer-001&rank=2; Trial registration number: NCT01201837.
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Translational perspective
Although there is extensive epidemiological and pre-clinical evidence supporting favourable cardiovascular effects of HDL, clinical trials of
HDL-based therapies have often yielded disappointing results. Here,we report the results of the CHI-SQUARE study, the largest randomized
clinical trial performed so far of serial HDL infusions in patients with a recent acute coronary syndrome. In this study, the HDL-mimetic agent
CER-001 did not reduce coronaryatherosclerosis on IVUS and QCAwhen compared with placebo. Whether CER-001 administered in other
regimens or to other populations could favourably affect atherosclerosis is not known.
Introduction
Patients with a recent acute coronary syndrome are exposed to
a high risk of recurrent events during the first year after the initial
presentation despite intensive contemporary treatment.1 Athero-
sclerosis is the main underlying aetiology for the important cardiovas-
cular disease burden in our societies.2 Therefore, further strategies
to decrease atherosclerosis burden and improve cardiovascular out-
comes are needed. There is an inverse association between high-
density lipoprotein (HDL) cholesterol and risk of coronary heart
disease complications in population-based epidemiological studies,3
although HDL particle number appears to be a better predictor of
outcomes in the current era of aggressive statin use and very low
LDL cholesterol levels.4 Yet recent data have indicated that this
inverse relationship is substantially weakened in patients with mani-
fest coronary heart disease.5 Several trials have reported disappoint-
ing results with medications affecting HDL such as niacin and
cholesteryl ester transfer protein inhibitors, although some of
these studies may havecontainedconfounding factors.6– 9 Three clin-
ical studies have suggested benefits of HDL infusions on coronary
plaque burden evaluated by intravascular ultrasonography (IVUS)
when compared with baseline, but none established significance vs.
placebo.10 –12 Interpretation of the latter studies was limited by the
small sample sizes10– 12 and imbalances among groups in plaque
burden at baseline.10
CER-001 is an engineered lipoprotein particle mimicking
pre-beta HDL and consisting of a combination of recombinant
human apolipoprotein A-I and two phospholipids. It has previously
been shown to rapidly mobilize large amounts of cholesterol into
the HDL fraction following its i.v. administration.13 The objective
of the current study was to assess the safety and efficacy of
CER-001 administered as a series of weekly infusions on coronary
atherosclerosis as assessed by IVUS and quantitative coronary angi-
ography (QCA).
Methods
Study design and population
Between March 2011 and August 2012, patients with a clinical indication
for coronary angiography and a research-mandated IVUS recording
approved by the IVUS core laboratory were randomized to receive
either placebo or CER-001 infusions within 14 days of having an acute
coronary syndrome defined as unstable angina, non-ST or ST segment
elevation myocardial infarction. Eligible patients were women (without
childbearing potential) and men up to 80 years of age with at least one
narrowing of 20% or more on coronary angiography at baseline or
history of percutaneous coronary intervention (PCI) (the infarct-related
artery and all coronary arteries undergoing PCI were excluded from the
imaging analysis). Patients with .50% stenosis in the left main coronary
artery, a baseline IVUS recording determined to be of unacceptable
quality by the IVUS core laboratory, renal insufficiency (serum creatinine
.2.0 mg/dL), liver disease (enzymes greater than twice the upper limit of
normal), uncontrolled diabetes mellitus (HbA1C .10%), triglycerides
.500 mg/dL, uncontrolled hypertension, haemodynamic instability,
class III or IV heart failure, known ejection fraction ,35%, previous or
planned coronary bypass surgery, valvular disease requiring cardiac
surgery, or history of alcohol or drug abuse were excluded from study
participation. Institutional ethics committees approved the protocol at
all 51 participating study centres in the USA, the Netherlands, Canada,
and France, and all trial patients provided written informed consent
before any study procedure was performed.
The CHI-SQUARE study was a randomized, double-blinded, placebo-
controlled, ascending dose trial. Qualifying patients were randomly
assigned to receive six weekly volume-matched infusions of either
CER-001 or placebo in a 3 : 1 ratio in three consecutive cohorts
(CER-001 3 mg/kg vs. placebo, then 6 mg/kg vs. placebo, and finally
12 mg/kg vs. placebo), resulting in similar numbers of patients randomized
to the four study arms (placebo, CER-001 3, CER-001 6, and CER-001
12 mg/kg). The randomization code used blocks of size 4 and was stratified
according to site and cohort, and was generated by the Montreal Heart
Institute Coordinating Center using the SAS procedure PROCPLAN and
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managed centrally via an interactive response system to ensure an ascend-
ing dose study design.
Prior to randomization, a baseline IVUS examination of the designated
target coronary artery was performed and transferred to the Montreal
Heart Institute core IVUS laboratory for a quality assessment. The prox-
imal 4 cm of the target coronary artery in which IVUS was performed at
baseline needed to have a reference diameter of 2.5 mm or more, be free
of filling defects suggestive of thrombosis, not to have.50% reduction in
lumen diameter by visual angiographic estimation at baseline, and not to
have undergone previous PCI nor be a candidate for intervention at the
time of the baseline catheterization or over the following 12 weeks.
Threeweeks after the last study infusion (2–5 week window), a follow-up
IVUS examination was performed in the same segment of the target
artery studied at baseline.
A follow-up visit occurred 6 months after the last dose of study
medication to monitor for major adverse cardiovascular events and
anti-apoA-I antibodies. Patient safety was monitored throughout the
trial. Clinical blood laboratory data were evaluated on an ongoing basis
throughout the study. An independent, unblinded safety monitoring
committee met at intervals during the trial (including near the end of
the recruitment of the first two cohorts to authorize dose escalation).
Intervention and blinding
CER-001 (Cerenis, France) is a negatively charged lipoprotein complex
mimicking discoidal pre-beta HDL, consisting of recombinant human
apolipoprotein A-I and a combination of two naturally occurring
phospholipids. The apolipoprotein A-I component is expressed in
mammalian CHO cells and purified by a three-step column chromatog-
raphy process. The phospholipid component consists of egg sphingo-
myelin and 1,2-dihexadecanoyl-sn-glycero-3-phospho-(1′-rac-glycerol)
(dipalmitoylphosphatidyl-glycerol) in a 97 : 3 weight ratio. The ratio
of protein to total phospholipids in the CER-001 complex is 1 : 2.7
weight/weight. The drug product is a solution of the CER-001 complexes
in phosphate buffered sucrose/mannitol solution (10 mM phosphate
buffer, 4.0% sucrose, 2.0% mannitol, pH 8.0). The concentration of
CER-001 complexes in the formulation is expressedas the concentration
of the apolipoprotein A-I component. Intravenous infusions of CER-001
or placebo (saline with all non-active ingredients of CER-001) were
administered over 1 h.
The site pharmacist or designee dispensing study drug was unblinded
to individual patient treatment allocation but had no other role in study
conduct. All other site personnel, the patients, blinded study monitor,
study management team, and sponsor, were blinded to treatment alloca-
tion. Study drug blinding was achieved by shrouding the i.v. container with
an opaque bag, sealed by the pharmacist. Both the placebo saline solution
and CER-001 solutions remained shrouded until the infusions were
administered and returned to the pharmacy.
Intravascular ultrasonography and coronary
angiography
The methods for IVUS image acquisition and measurement in athero-
sclerosis studies have been described previously.11,14– 18 Intravascular
ultrasonographyexaminations wereperformed using 40–45 MHzcathe-
ters at baseline and follow-up. The same type of IVUS catheter (Volcano
Corp or Boston Scientific) was used and the same dose of intracoronary
nitroglycerine (0.15 mg) was administered prior to automated IVUS
pullbacks performed at both time-points. All IVUS examinations were
analysed at the Montreal Heart Institute core laboratory by experienced
technicians supervised by a cardiologist blinded to treatment assignment,
according to published standards.19 The lumen and external elastic
membrane borders were manually traced on 31 digitized cross-sections
matchedat baseline and follow-up (fewer if it wasnotpossible tooptimal-
ly match 31 cross-sections, but at least 16 matched frames were traced at
both time-points in all cases) and selected throughout the segment of
interest. The total atheroma volume was computed through the summa-
tion of plaque areas (the latter is equal to the external elastic membrane
area minus the lumen area) of all traced cross-sections for the segment,
and results were then indexed to a 30-mm segment to compensate
for differences in segment length between subjects and to allow each
patient to contribute equally to the overall result (indexation to a
30-mm segment was performed by dividing atheroma volume by the
length of the reconstructed segment and multiplying by 30). Per cent
atheroma volume was computed by dividing atheroma volume by exter-
nal elastic membrane volume and then multiplying by 100%.
Care was taken to ensure identical conditions during the angiographic
examinations at baseline and follow-up (catheters, contrast media, and
projections). Intracoronary nitroglycerine (0.15 mg) was administered
into each coronary artery before angiographic injection. The segments
of interest were visualized in multiple transverse and sagittal views to
clearly separate stenosis from branches, minimize foreshortening, and
obtain views as perpendicular as possible to the long axis of the segments
to be analysed. All angiograms were analysed at the MHI QCA core
laboratory using the CMS system (MEDIS, Leiden, Netherlands).20,21
Quantitative coronary angiography was performed by experienced tech-
nicians supervised by an expert physician in matched projections from
baseline and follow-up angiograms.17 For each lesion, an end-diastolic
frame from both angiograms was selected with identical angulations
that best showed the stenosis at its most severe degree with minimal
foreshortening and branch overlap. All intervened coronary arteries
were excluded from the analysis. The coronary artery segments analysed
included all those with a reference diameter ≥1.5 mm and a stenosis
≥20% at baseline, and those with new lesions at follow-up. Computer
software automatically calculated the minimum lumen diameter
(MLD), reference diameter, and per cent diameter stenosis.
Efficacy parameters
The primary efficacy endpoint was the nominal change in the total
atheroma volume (follow-up minus baseline) on IVUS. Secondary and
exploratory efficacy measures included, respectively, the nominal
change in per cent atheroma volume on IVUS, and the nominal changes
in the coronary artery score (defined as the per-patient mean of MLD
for all lesions measured) and in the cumulative coronary stenosis score
(calculated as the summation of the per cent diameter stenosis of all
lesions measured) on QCA. The cumulative coronary stenosis score is
an index of the anatomic extension and severity of disease in all coronary
arteries.22
Safety and clinical event evaluations
Patient safety was assessed by monitoring adverse events, physical
examinations, electrocardiograms, and clinical laboratory results. All
blood-related analyses were carried out centrally. A clinical endpoint
committee adjudicated all major adverse cardiovascular events having
occurred between the first administration of study drug and 6 months
after the last administration of study drug, including death, resuscitated
cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, coronary
revascularization procedures (PCI and coronary bypass graft surgery),
hospitalization for unstable angina and hospitalization for heart failure,
according to established definitions.
Statistical analysis
The primary analysis was based on the modified intent-to-treat popula-
tion, which included all randomized subjects with a post-randomization
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efficacy recording, irrespective of their protocol adherence. A sensitivity
analysis was performed on the per-protocol population, which included
subjects who were part of the modified intent-to-treat population and
received all six infusions of study drug at the planned dosage without
major protocol deviations. Safety results are presented for all patients
who received at least one study infusion.
Parametric analyses were performed after basic assumptions were
checked. The primary endpoint (nominal change in the total atheroma
volume) was analysed using an analysis of a covariance model that
included the treatment group and baseline value as a covariate. The
adjusted mean in the CER-001 12 mg/kg group was compared with the
adjusted mean in the placebo group at the 0.05 significance level and
this comparison was considered as the primary analysis. Under the
same analysis of the covariance model, the adjusted means in the other
CER-001 groups (6 and 3 mg/kg) were compared with the adjusted
mean in the placebo group; the change from baseline within each treat-
ment group was also tested. These analyses of the primary endpoint
were considered exploratory. Other IVUS and QCA endpoints
expressed as a nominal change from baseline to follow-up were analysed
as described above using an analysis of the covariance model adjusting for
the baseline value of the parameter.
Sample size computation was based on an expected difference of at
least 7 mm3 in change in the total atheroma volume between the
CER-001 12 mg/kg and placebo groups. Assuming that the standard de-
viation of the change in the total atheroma volume would be 15 mm3
in both groups and using a two-sided 0.05 significance level, 98 subjects
per treatment group were necessary to detect this difference with 90%
power. To account for an attrition rate of 20–25%, 126 subjects per
group were to be randomized for a total of 504 patients. Statistical
analyses were performed using SAS version 9.3.
Results
Baseline demographics
Five hundred and seven patients were randomized (Figure 1) and
baseline patient characteristics were similar among groups
(Table 1). There were 417 and 461 patients with paired IVUS and
QCA measurements, respectively. The main reasons for the lack of
IVUS analysis were early study termination and inability to obtain a
matched coronary segment at both time points (Figure 1). The per-
centages of patients who received all six planned study drug infusions
in the primary analysis (modified intent-to-treat) population were
97.5, 100, 96.7, and 91.4% in the placebo, CER-001 3, 6, and 12 mg/kg
groups (P¼ 0.004).
Imaging efficacy results
Intravascular ultrasonography images were traced over a mean arter-
ial segment length of 48+ 15 mm (Table 2). The mean total ather-
oma volume at baseline was 155.24+67.99 mm3. The adjusted
means for change in the total atheroma volume were 22.71,
23.13, 21.50, and 23.05 mm3 in the placebo, CER-001 3, 6, and
12 mg/kg groups (P ¼ 0.81 for the pre-specified primary analysis of
12 mg/kg vs. placebo). There were also no differences compared
with placebo for the CER-001 6 mg/kg (nominal P ¼ 0.45) and
3 mg/kg (nominal P ¼ 0.77) groups. The change in per cent atheroma
volume was similar among all study groups [0.02, 20.02, 0.01, and
0.19% in the placebo, CER-001 3 mg/kg (P ¼ 0.86), 6 mg/kg (P ¼
0.95), and 12 mg/kg (P ¼ 0.53) groups (nominal P-values vs.
placebo)]. A sensitivity analysis conducted on the per-protocol popu-
lation, which had 97% power to detect the target difference given the
observed standard deviation, yielded similar results (Table 2).
Quantitative coronaryangiography results aredescribed inTable4.
The change from baseline to follow-up in the coronary artery score
was 20.022, 20.036, 20.022, and 20.015 mm in the placebo and
CER-001 3, 6, and 12 mg/kg groups, respectively (vs. placebo,
nominal P ¼ 0.25, 0.99, 0.55, respectively). The change from baseline
to follow-up in the cumulative coronary stenosis score was 20.51,
2.65, 0.71, and 20.77% in the placebo and CER-001 3, 6, and
12 mg/kg groups (nominal P ¼ 0.01 for 3 mg/kg vs. placebo).
Cardiovascular events
The number of patients with at least one major adverse cardiovascu-
lar event was 10 (8.3%) in the placebo group, and 16 (13.3%), 17
(13.7%), and 12 (9.8%) in the CER-001 groups, without statistically
significant differences (Table 5).
Safety results
CER-001wasgenerallywell toleratedduring the study (Table 6).There
were a few infusion-type reactions during the study, which led to the
temporary halting of patient recruitment (without interrupting
ongoing study drug administration) to allow updating of the informed
consent document as per the recommendation of the safety monitor-
ing committee following its periodic review which included all subjects
from the first two study cohorts and 128 subjects from the third
cohort. Drug-related hypersensitivity reported as a serious adverse
event occurred in 0, 1, 3, and 2 patients in the placebo and CER-001
groups. Treatment-emergent infusion-type reactions (with rigors,
chills, nausea, and/or hypotension) occurred in 0, 0, 3, and 3 patients
of the placebo, CER-001 3, 6, and 12 mg/kg groups, respectively.
None of these patients had anti-apoA-I antibodies.
Treatment-emergent elevations in ALT (three times the ULN) oc-
curred in 2, 2, 2, and 1 patients in the four study groups.
Post hoc re-analysis
At the end of the study, the sponsor requestedapost hoc re-analysis of
the IVUS recordings by a separate group, which also showed that the
primary endpoint was not met (Table 3). The adjusted means for
change in the total atheroma volume were 22.85, 24.76, 23.34,
and 22.61 mm3 in the placebo, CER-001 3 mg/kg (P ¼ 0.28), 6 mg/kg
(P ¼ 0.78), and 12 mg/kg (P ¼ 0.89) groups (nominal P-values vs.
placebo). A sensitivity analysis performed on the per-protocol
population of these post hoc re-analysed data yielded similar results
(Table 3).
Discussion
This study did not demonstrate positive effects of the HDL-mimetic
agent CER-001 on coronary atherosclerosis evaluated by IVUS and
QCA. In the main modified intent-to-treat population, the differences
in adjusted means of change in the total atheroma volume (active arm
minusplacebo)were20.34 mm3 forCER-00112 mg/kg (primaryend-
point, P ¼ 0.81), 1.20 mm3 for 6 mg/kg, and20.42 mm3 for 3 mg/kg. In
the per-protocol population, corresponding changes vs. placebo were
20.51, 0.90, and 22.00 mm3 for the CER-001 12, 6, and 3 mg/kg
groups, respectively. The difference of 22 mm3 between the
J.-C. Tardif et al.3280
Figure 1 Disposition of patients in the trial.
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CER-0013 mg/kgandplacebogroupson IVUS in that sensitivityanalysis
was small and not nominally significant (nominal P ¼ 0.22). Thepost hoc
re-analysis of IVUS recordings requested by the sponsor yielded results
similar to those of the pre-specified primary analysis.
This result on IVUS was accompanied by an increase of 3.15% of
the cumulative coronary stenosis score on QCA in the CER-001
3 mg/kg group compared with placebo (nominal P ¼ 0.01), which
suggests that therewasprogressively greaterobstructionof coronary
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Table 1 Characteristics of patients in the modified intent-to-treat population (n5 470)
Randomization group Placebo
(n5 118)
CER-001, 3 mg/kg
(n5 116)
CER-001, 6 mg/kg
(n 5 120)
CER-001, 12 mg/kg
(n 5 116)
Age (years), means+ SD 59.0+9.0 57.3+9.3 59.1+9.3 60.5+9.6
Men, n (%) 86 (72.9) 93 (80.2) 90 (75.0) 85 (73.3)
Weight (kg), means+ SD 90.2+15.3 89.2+17.8 89.8+17.3 89.5+19.5
Current smoking, n (%) 30 (25.4) 34 (29.3) 31 (25.8) 31 (26.7)
Hypertension, n (%) 89 (75.4) 82 (70.7) 82 (68.3) 71 (61.2)
Diabetes, n (%) 36 (30.5) 27 (23.3) 29 (24.2) 25 (21.6)
Prior MI, n (%) 26 (22.0) 19 (16.4) 16 (13.3) 12 (10.3)
Prior PCI, n (%) 42 (35.6) 30 (25.9) 31 (25.8) 19 (16.4)
Lipid-lowering agent use, n (%) 114 (96.7) 114 (98.3) 116 (96.8) 113 (97.4)
Apo-B (mg/dL), Mean+ SD 79.9+21.5 78.7+22.8 85.7+25.8 81.1+23.4
Apo A-I (mg/dL), Mean+ SD 130.2+21.7 129.7+22.2 131.1+22.9 134.7+22.9
Presentation, n (%)
Unstable angina 65 (55.1) 68 (58.6) 53 (44.2) 60 (51.7)
NSTEMI 41 (34.7) 37 (31.9) 59 (49.2) 50 (43.1)
STEMI 12 (10.2) 11 (9.5) 8 (6.7) 6 (5.2)
Apo, apolipoprotein; MI, myocardial infarction; PCI, percutaneous coronary intervention.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Primary intravascular ultrasonography results
Modified intent-to-treat population,
total atheroma volume (mm3)
Placebo
(n5 101)
CER-001, 3 mg/kg
(n5 105)
CER-001, 6 mg/kg
(n 5 106)
CER-001, 12 mg/kg
(n5 105)
Baseline (means+ SD) 160.57+59.99 141.01+60.91 162.13+78.86 157.37+68.98
Follow-up (means+ SD) 157.70+59.08 138.32+59.43 160.41+77.81 154.26+67.43
Nominal change (adjusted mean) (95% CI) 22.71 (24.89, 20.53) 23.13 (25.03,21.24) 21.50 (23.76, 0.75) 23.05 (24.79,21.30)
P-value vs. placebo N/A 0.77 0.45 0.81*
Per cent atheroma volume (%)
Baseline (mean+ SD) 38.03+8.97 34.63+9.13 37.37+9.32 36.86+9.09
Follow-up (mean+ SD) 38.01+8.90 34.69+8.91 37.35+8.97 37.04+9.22
Nominal change (adjusted mean) (95% CI) 0.02 (20.31, 0.35) 20.02 (20.35, 0.31) 0.01 (20.31, 0.33) 0.19 (20.22, 0.60)
P-value vs. placebo N/A 0.86 0.95 0.53
Per-protocol population, total atheroma volume (mm3) (n ¼ 82) (n ¼ 78) (n ¼ 80) (n ¼ 78)
Baseline (means+ SD) 158.65+58.98 141.66+64.10 160.79+77.61 153.86+65.93
Follow-up (means+ SD) 156.17+58.39 137.67+61.93 159.14+76.49 151.01+65.34
Nominal change (adjusted mean) (95% CI) 22.34 (24.71, 0.03) 24.34 (26.48,22.19) 21.45 (24.17, 1.27) 22.85 (24.85,20.85)
P-value vs. placebo N/A 0.22 0.62 0.74
Per cent atheroma volume (%)
Baseline (mean+ SD) 37.59+9.01 34.10+8.71 37.37+9.63 36.93+9.00
Follow-up (mean+ SD) 37.58+9.00 34.12+8.58 37.30+9.25 37.02+9.27
Nominal change (adjusted mean) (95% CI) 0.02 (20.34, 0.38) 20.05 (20.45, 0.34) 20.05 (20.42, 0.33) 0.10 (20.41, 0.61)
P-value vs. placebo N/A 0.78 0.80 0.80
*P-value for primary endpoint (in bold). All other P-values represent nominal values.
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arteries on QCA at this dose.22 The difference among groups for the
change in the coronaryartery score,however, did not reach statistical
significance.
In the exploratory analysis of major adverse cardiovascular events,
there was no statistically significant difference in the time to first
event analysis or in the individual clinical endpoints, although this
study was not powered for these outcomes.
Although CHI-SQUARE is much larger than the previous three
clinical studies of HDL infusions,9 –11 none of these trials has been
able to demonstrate a therapeutic benefit on coronary atheroscler-
osis evaluated by IVUS compared with placebo using the
intention-to-treat principle. Given that all four studies have focused
on patients with a recent acute coronary syndrome, it is not
known if CER-001 could be effective in other patient populations.
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Table 4 Quantitative coronary angiography results
Modified intent-to-treat population,
coronary artery score (mm)
Placebo
(n 5 116)
CER-001, 3 mg/kg
(n 5 115)
CER-001, 6 mg/kg
(n5 119)
CER-001, 12 mg/kg
(n 5 111)
Baseline (means+ SD) 1.961+0.385 2.034+0.392 2.003+0.438 1.985+0.499
Follow-up (means+ SD) 1.940+0.384 1.997+0.382 1.981+0.436 1.970+0.502
Nominal change (adjusted mean) (95% CI) 20.022 (20.039, 20.006) 20.036 (20.052,20.020) 20.022 (20.038,20.006) 20.015 (20.032, 0.001)
P-value vs. placebo N/A 0.25 0.99 0.55
Cumulative coronary stenosis score (%)
Baseline (means+ SD) 167.66+100.73 169.27+105.90 181.23+109.01 165.81+111.18
Follow-up (means+ SD) 167.13+101.04 171.90+108.72 182.00+109.41 165.01+111.20
Nominal change (adjusted mean)
(95% CI)
20.51 (22.42, 1.41) 2.65 (1.00, 4.29) 0.71 (21.40, 2.82) 20.77 (22.66, 1.13)
P-value vs. placebo N/A 0.01 0.40 0.85
Given that the P-value for the primary endpoint was not significant, all P-values in this table represent nominal values.
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Table 3 Post hoc reanalysis of intravascular ultrasonography data
Modified intent-to-treat population,
total atheroma volume (mm3)
Placebo
(n 5 93)
CER-001, 3 mg/kg
(n5 88)
CER-001, 6 mg/kg
(n 5 100)
CER-001, 12 mg/kg
(n5 88)
Baseline (means+ SD) 148.34+57.06 133.54+51.97 149.16+72.19 146.21+60.81
Follow-up (means+ SD) 145.32+55.58 129.23+50.92 145.63+70.97 143.52+59.09
Nominal change (adjusted mean) (95% CI) 22.85 (25.27,20.43) 24.76 (27.25, 22.26) 23.34 (25.67,21.00) 22.61 (25.10,20.13)
P-value vs. placebo N/A 0.28 0.78 0.89
Per cent atheroma volume (%)
Baseline (means+ SD) 36.35+9.11 34.54+8.11 36.67+9.09 35.87+8.70
Follow-up (means+ SD) 36.16+9.12 34.04+7.81 36.23+8.87 36.09+8.95
Nominal change (adjusted mean) (95% CI) 20.17 (20.66, 0.33) 20.56 (21.07, 20.05) 20.41 (20.89, 0.06) 0.22 (20.28, 0.73)
P-value vs. placebo N/A 0.27 0.48 0.28
Per-protocol population, total atheroma volume (mm3) (n ¼ 67) (n ¼ 66) (n ¼ 72) (n ¼ 65)
Baseline (mean+ SD) 150.35+56.90 134.97+53.82 146.44+72.47 144.93+61.52
Follow-up (mean+ SD) 146.41+54.84 129.16+52.13 143.50+69.58 143.08+60.07
Nominal change (adjusted mean) (95% CI) 23.63 (26.34,20.91) 26.28 (29.02, 23.54) 22.83 (25.44,20.21) 21.81 (24.56, 0.95)
P-value vs. placebo N/A 0.18a 0.68 0.36
Per cent atheroma volume (%)
Baseline (mean+ SD) 36.91+8.88 34.10+7.44 36.92+9.42 36.10+8.41
Follow-up (mean+ SD) 36.59+8.90 33.45+7.21 36.40+9.13 36.47+8.78
Nominal change (adjusted mean) (95% CI) 20.28 (20.87, 0.31) 20.74 (21.33, 20.14) 20.48 (21.04, 0.09) 0.37 (20.22, 0.97)
P-value vs. placebo N/A 0.28 0.63 0.13
aIn a non-parametric test not performed by the academic statistical centre, the nominal P was 0.03.
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Whether other dosing regimens (e.g. higher number of infusions, dif-
ferent dosage) could lead to a more favourable outcome is also
unknown. It is also possible that the different lipoprotein composi-
tions of these four HDL-related complexes may affect their effective-
ness. The fact that the dose-related increase in cholesterol
mobilization in the current study (estimated by the increase in
plasma cholesterol after CER-001 infusion, see Supplementary
Data) did not translate into progressively greater effects on IVUS
underscores the lack of predictive value of this biomarker. Other
properties of HDL particles, like their anti-inflammatory effects23
or changes in their proteome,24 could be of greater importance.
Nevertheless, the plasma level of free cholesterol increased by
45% at 2 h after the start of the infusion of CER-001 12 mg/kg.
The significance of this result obtained at a single time point after in-
fusion is not entirely clear. Interestingly, in a previous phase I clinical
study, significant increases in the plasma level of cholesteryl esters
were observed after the infusion of CER-001 at dosages of 15 and
45 mg/kg.13 In that study, no clinically significant changes in laboratory
red blood cell parameters were observed in humans with CER-001
doses up to 45 mg/kg. Similarly, no changes in red blood cell
morphologic parameters were observed in in vitro compatibility
studies using humanredbloodcells andCER-001 at a30-fold concen-
tration margin over the highest dose used in the current study. Al-
though its source is not entirely certain, the majority of the
cholesterol mobilized into circulation likely comes from the liver,
as previously proposed.25
There were six patients treated with CER-001 who experienced
non-fatal infusion reactions (3 with 6 mg/kg and 3 with 12 mg/kg).
Thepathophysiologyof these reactions is uncertain, butnot associated
with anti-apoA-I antibodies or obvious complement depletion. An
infusion reaction was also reported in the apoA-I Milano study.9
One study limitation was that it was not powered to detect
differences in clinical outcomes among groups. Also, there was no
assessment of potential changes in plaque quality by virtual histology,
which may have concealed potentially favourable effects of this thera-
peutic approach in the long term. Increasing emphasis is indeed being
placed on the stability or instability of atherosclerotic plaques and the
associated risk of rupture.
In conclusion, when compared with placebo, infusions of CER-001
did not result in a significant reduction in coronary atherosclerosis
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Table 5 Major adverse cardiovascular events (positively adjudicated) occurring between the first administration of study
drug and 6 months after the last dose of study drug in patients who received at least one infusion of study drug
Patients with at least one event Placebo
(n 5 120)
CER-001, 3 mg/kg
(n5 120)
CER-001, 6 mg/kg
(n 5 124)
CER-001, 12 mg/kg
(n 5 122)
Any MACE 10 (8.3%) 16 (13.3%) 17 (13.7%) 12 (9.8%)
P-value (log-rank) N/A 0.24 0.19 0.69
Death 0 0 0 0
Cardiac arrest 0 0 0 0
Non-fatal MI (%) 1 (0.8) 1 (0.8) 3 (2.4) 4 (3.3)
Non-fatal stroke (%) 0 (0) 1 (0.8) 1 (0.8) 0 (0)
Coronary revascularization (%) 8 (6.7) 13 (10.8) 12 (9.7) 8 (6.6)
Hospitalization for unstable angina (%) 5 (4.2) 4 (3.3) 2 (1.6) 2 (1.6)
Hospitalization for heart failure (%) 0 (0) 1 (0.8) 1 (0.8) 1 (0.8)
Given that the P-value for the primary endpoint was not significant, all P-values in this table represent nominal values. All MACEs were adjudicated by a clinical endpoint adjudication
committee.
MACE, major adverse cardiovascular event; MI, myocardial infarction.
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Table 6 Selected adverse events in patients who received at least one infusion of study drug
Safety population Placebo (n5 120) CER-001, 3 mg/kg (n 5 120) CER-001, 6 mg/kg (n5 124) CER-001, 12 mg/kg (n 5 122)
Any serious AE (%) 8 (6.7) 14 (11.7) 14 (11.3) 11 (9.0)
Any adverse event (%) 96 (80.0) 98 (81.7) 86 (69.4) 90 (73.8)
Infusion-type reaction (%) 0 (0) 0 (0) 3 (2.4) 3 (2.5)
Drug hypersensitivity (%) 2 (1.7) 1 (0.8) 3 (2.4) 6 (4.9)
Rash (%) 0 (0) 2 (1.7) 1 (0.8) 3 (2.5)
Dyspnoea (%) 3 (2.5) 3 (2.5) 6 (4.8) 7 (5.7)
Nausea (%) 8 (6.7) 11 (9.2) 4 (3.2) 2 (1.6)
Diarrhoea (%) 3 (2.5) 7 (5.8) 4 (3.2) 3 (2.5)
AE, adverse event.
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as assessed by IVUS and QCA. Whether or not the non-significant
reduction in coronary atheroma burden in those treated with
CER-001 3 mg/kg reflects a beneficial effect of this lower dose will
have to await further investigation.
Supplementary material
Supplementary material is available at European Heart Journal online.
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